Home » Stocks » CVM

Cel-Sci Corporation (CVM)

Stock Price: $22.36 USD 0.19 (0.86%)
Updated Jun 21, 2021 11:54 AM EDT - Market open
Market Cap 942.87M
Revenue (ttm) 226,299
Net Income (ttm) -35.13M
Shares Out 40.03M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $22.36
Previous Close $22.17
Change ($) 0.19
Change (%) 0.86%
Day's Open 22.46
Day's Range 22.10 - 22.80
Day's Volume 473,556
52-Week Range 10.76 - 40.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces the closing of $31.7 million bought deal offering.

1 week ago - Business Wire

CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% discount ...

1 week ago - Benzinga

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.

1 week ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)-- #CVM--CEL-SCI Announces Bought Deal Offering

1 week ago - Business Wire

Big news is coming for CEL-SCI, and we don't know which way the stock will move.

2 weeks ago - The Motley Fool

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2021 financial results.

1 month ago - Business Wire

Reddit stocks always make noise across social media platforms. But these investments have serious catalysts connected to them.

Other stocks mentioned: CTRM, MMEDF, MRO, SPPI, YCBD
2 months ago - InvestorPlace

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports first quarter fiscal 2021 financial results.

4 months ago - Business Wire

Investors are betting that these three stocks could turn them into millionaires in incredibly short periods of time. Will they succeed?

Other stocks mentioned: AMC, BB
4 months ago - The Motley Fool

CVM stock is on the move after Cel-Sci CEO Geert Kersten joined the battle against GME stock short-sellers. Here's what to know.

4 months ago - InvestorPlace

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference

5 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation issues letter to shareholders.

5 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI reports fiscal 2020 financial results and clinical & corporate developments.

5 months ago - Business Wire

Data lock has been announced, and top line data is to be expected within a few weeks. Trial duration hints towards longer survival than Standard of Care.

6 months ago - Seeking Alpha

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference

6 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces the closing of its $14.65 million bought deal.

6 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Bought Deal Offering.

6 months ago - Business Wire

Data is Locked. NWBO's Data Lock announcement boosted their Market Cap to nearly $2B.

6 months ago - Seeking Alpha

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Update on Phase 3 Cancer Trial Results.

6 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies.

6 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at H.C.

9 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports third quarter fiscal 2020 financial results.

10 months ago - Business Wire

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment.

10 months ago - Business Wire

CEL-SCI: What's Next

1 year ago - Seeking Alpha

Cel-Sci: A Zombie Biotech Company

1 year ago - Seeking Alpha

CEL-SCI's Multikine: Can It Really Be This Good?

1 year ago - Seeking Alpha

Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?

1 year ago - The Motley Fool

Cel-Sci: It's All Happening

1 year ago - Seeking Alpha

CEL-SCI announced that it is developing an immunotherapy for COVID-19 based on its LEAPS peptide technology.

1 year ago - Seeking Alpha

CEL-SCI: LEAPS & COVID-19

1 year ago - Seeking Alpha

Cel-Sci: The Upside Is Still There

1 year ago - Seeking Alpha

Cel-Sci: Little Known Drug Validates Multikine's Investigation Goals

1 year ago - Seeking Alpha

CEL-SCI: Food For Thought Before The Big Day

1 year ago - Seeking Alpha

CEL-SCI: The Homestretch

1 year ago - Seeking Alpha

The mechanism of action for cytokines in helping the immune system respond to malignant growth in the head and neck has been well documented by medical research.

1 year ago - Seeking Alpha

Multikine's Phase 3 trial accounts for the short half-lives of cytokines post administration, which may lead to significant improvements in its clinical profile compared to Phase 2.

1 year ago - Seeking Alpha

The world's largest head and neck cancer study should have ended in late 2018 but patients appear to be living longer.

1 year ago - Seeking Alpha

The world's largest head and neck cancer study should have ended in late 2018, but patients appear to be living longer.

1 year ago - Seeking Alpha

Multikine is a cytokine-based immunotherapeutic compound intended to cure Head and Neck Squamous-Cell Carcinoma, which is currently being tested in a large Phase III trial.

1 year ago - Seeking Alpha

These stocks were huge winners last week. But can their momentum continue?

Other stocks mentioned: GTHX, PFE
1 year ago - The Motley Fool

May 8, 2019 Cel-Sci Corporation released a letter to investors indicating the Phase 3 Multikine trial had not yet reached its endpoint of 298 endpoints (deaths) in the two arms.

2 years ago - Seeking Alpha

CEL-SCI's Multikine Phase III Trial in Squamous Cell Cancer of Head and Neck Continues as the End-Point Has Still Not Yet Been Reached.

2 years ago - Seeking Alpha

About CVM

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 1, 1987
CEO
Geert Kersten
Country
United States
Stock Exchange
NYSEAMERICAN
Ticker Symbol
CVM
Full Company Profile

Financial Performance

In 2020, CVM's revenue was $597,427, an increase of 11.51% compared to the previous year's $535,776. Losses were -$30.28 million, 36.8% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CVM is 19.00, which is a decrease of -15.03% from the latest price.

Price Target
$19.00
(-15.03% downside)